| Market Cap | 120.26M | P/E | - | EPS this Y | -77.80% | Ern Qtrly Grth | - |
| Income | -14.69M | Forward P/E | 3.00 | EPS next Y | 3,000.00% | 50D Avg Chg | -16.00% |
| Sales | 38.05M | PEG | 2.14 | EPS past 5Y | - | 200D Avg Chg | -5.00% |
| Dividend | N/A | Price/Book | 105.00 | EPS next 5Y | 25.00% | 52W High Chg | -53.00% |
| Recommedations | 2.00 | Quick Ratio | 0.95 | Shares Outstanding | 73.54M | 52W Low Chg | 68.00% |
| Insider Own | 14.53% | ROA | -10.27% | Shares Float | 54.65M | Beta | 0.69 |
| Inst Own | 7.73% | ROE | -43.49% | Shares Shorted/Prior | 3.27M/3.50M | Price | 1.68 |
| Gross Margin | 32.18% | Profit Margin | -38.62% | Avg. Volume | 1,787,579 | Target Price | 12.00 |
| Oper. Margin | -18.01% | Earnings Date | Nov 4 | Volume | 610,721 | Change | 3.07% |
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.